Purpose: Currently, quality control (QC) for each IMRT treatment is performed by dose distribution measurements. These techniques are very time-consuming and require long accelerator downtime. QC could be only based in verification of monitor units and dose distributions, if precise control of MLC is carried out. In such a manner, the e-IMRT platform (http://eimrt.cesga.es/) is a remote distributed computing tool, which allows comparison between the dose distributions calculated by a TPS and those calculated by Monte Carlo (MC).
Methods: Previously, our linear accelerator (Oncor Impression, Siemens) was commissioned. For this purpose, comparison of experimental and MC simulated data was carried out. Several IMRT treatments plans were calculated in superposition algorithm (TPS Xio®CMS 4.60.00) and used as input data for the e-IMRT platform. These treatment plans were previously verified employing a 2D array MapCheckTM, Sun Nuclear. The gamma index (3%, 3mm) was used for validating results.
Results: The platform displays calculated doses using MC, also gamma map (in the CT images, not only statistical data) and histogram shown in Figures 1a), b) and d). The gamma map illustrates the differences between the input and calculated doses. According to the legend in Figure 1 d), these differences correspond to less than 1%. Results show good agreement between the doses calculated by TPS and those computed by e-IMRT platform.
Conclusions: If a rigorous quality control is established for MLC and optimisation criteria (number of gantry angles, minimum segment size, levels of intensity for fluency map) are used. Then, QC for IMRT standard treatment plans would be only based on the verification of monitor units and dose distributions using e-IMRT II.This work has been funded by the Xunta de Galicia, Project R&D Grant 09SIN007CT. We would like to thank Centro de Supercomputacià n de Galicia for the computational resources and support.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1118/1.4735477 | DOI Listing |
Pharmacol Res Perspect
February 2025
Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA.
Binimetinib is a MEK1/2 inhibitor particularly active in cells harboring activating mutations in the MAP kinase pathway, especially in BRAF and NRAS. Binimetinib, in combination with encorafenib, has received marketing approval in several jurisdictions for the treatment of patients with BRAF V600E or V600K mutant melanoma. The absorption, distribution, metabolism, and excretion of binimetinib were evaluated by administering a carbon 14-labeled binimetinib 45 mg dose (containing 40 μCi of radiolabeled material) to 6 healthy male participants.
View Article and Find Full Text PDFJ Diabetes
February 2025
Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Objective: To examine the relationship between serum carotenoid levels and cardiovascular-kidney-metabolic (CKM) syndrome in a representative sample of US adults.
Methods: Data from the fasting subsample of the NHANES 2017-2018 were analyzed using a survey-weighted approach to ensure the findings are representative of the broader US adult population. Serum levels of α-carotene, β-carotene, β-cryptoxanthin, lutein/zeaxanthin, and lycopene were measured using high-performance liquid chromatography.
Med Phys
January 2025
Department of Radiation Medicine and Applied Sciences, University of California at San Diego, La Jolla, California, USA.
Background: Proton pencil beam scanning (PBS) treatment planning for head and neck (H&N) cancers is a time-consuming and experience-demanding task where a large number of potentially conflicting planning objectives are involved. Deep reinforcement learning (DRL) has recently been introduced to the planning processes of intensity-modulated radiation therapy (IMRT) and brachytherapy for prostate, lung, and cervical cancers. However, existing DRL planning models are built upon the Q-learning framework and rely on weighted linear combinations of clinical metrics for reward calculation.
View Article and Find Full Text PDFACG Case Rep J
February 2025
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distribution. Disseminated HZ occurs when skin lesions erupt in numerous dermatomes. Upadacitinib is the first oral medication approved to treat moderate-severe Crohn's disease and has been associated with nonsevere cases of HZ.
View Article and Find Full Text PDFFluids Barriers CNS
January 2025
Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven - University of Leuven, O&N II Herestraat 49 box 820, 3000, Leuven, Belgium.
Background: Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain influx of protein therapeutics, is receptor-mediated transcytosis (RMT) by targeting nutrient receptors to shuttle protein therapeutics over the blood-brain barrier (BBB) along with their endogenous cargos. While higher brain exposure is achieved with RMT, the timeframe is short due to rather fast brain clearance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!